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DOI 10.1016/j.ccr.2012.04.038SUMMARYThe synthesis of dTDP is unique because there is a requirement for thymidylate kinase (TMPK). All other
dNDPs including dUDP are directly produced by ribonucleotide reductase (RNR). We report the binding of
TMPKandRNR at sites of DNA damage. In tumor cells, when TMPK function is blocked, dUTP is incorporated
during DNA double-strand break (DSB) repair. Disrupting RNR recruitment to damage sites or reducing the
expression of the R2 subunit of RNR prevents the impairment of DNA repair by TMPK intervention, indicating
that RNR contributes to dUTP incorporation during DSB repair. We identified a cell-permeable nontoxic
inhibitor of TMPK that sensitizes tumor cells to doxorubicin in vitro and in vivo, suggesting its potential as
a therapeutic option.INTRODUCTION
An important process during DNA repair is the availability of
a supply in sufficient amounts of four dNTPs (Niida et al.,
2010b). Ribonucleotide reductase (RNR)-mediated reduction
directly generates dADP, dGDP, dCDP, and dUDP from their
corresponding NDPs (Nordlund and Reichard, 2006). RNR is
composed of the R1 and R2 subunits, with the level of R2 being
subject to cell cycle regulation (Engstro¨m et al., 1985); R2 is often
found to be elevated in tumor cells (Jensen et al., 1994; Zhang
et al., 2009). It has been reported that R2 overexpression confers
oncogenic potential (Fan et al., 1998). An analog of R2, p53R2,
can be used to substitute for R2 in the RNR enzyme, and its func-
tion is important for DNA repair in quiescent cells (Ha˚kansson
et al., 2006; Pontarin et al., 2011). Nucleotide diphosphate kinase
converts all dNDPs to dNTPs, including dUTP. Pyrophosphorol-
ysis of dUTP by dUTPase or deamination of dCMP yields dUMP,Significance
The present study reveals that high levels of RNR at sites of D
seems to lead to dUTP incorporation during repair. Normal cycl
of R2 after DNA damage, thereby dispensing with the require
therapy by DNA damage is unable to discriminate between tu
can often lead to unwanted side effects. This study offers a st
that aims to minimizing side effects.
36 Cancer Cell 22, 36–50, July 10, 2012 ª2012 Elsevier Inc.which can then be converted to dTMP by thymidylate synthase.
The action of thymidine kinase (TK) is also able to generate dTMP
from thymidine. Thymidylate kinase (TMPK) subsequently cata-
lyzes the formation of dTDP (Reichard, 1988). Thus, dTDP is
the only dNDP formation that cannot be directly generated
through the action of RNR.
Repair of double-strand breaks (DSBs) is mediated by the
homologous recombination (HR), single-strand annealing
(SSA), or nonhomologous end-joining (NHEJ) pathways (Hartler-
ode and Scully, 2009). NHEJ occurs during G1 phase and facil-
itates the direct ligation of the two DNA ends that are associated
with DSBs (Lieber, 2010). Both the SSA andHRpathways involve
50 resectioning from a DSB site to generate a long 30 overhang
(Mimitou and Symington, 2009). The SSA pathway repairs
DSBs between or within linked direct repeats in which the 30
overhangs are annealed in a way that is dependent on the pres-
ence of these repeat sequences in the same DNA duplex, andNA damage in tumor cells without coordination with TMPK
ing cells, which have an intact checkpoint, express low levels
ment for TMPK during repair. Conventional cancer chemo-
mor cells and rapidly dividing cells in normal tissues, which
rategy by which TMPK is targeted as an adjunctive therapy
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to restore the continuous DNA duplex. HR repair at a DSB site
produces a long 30 single strand and employs DNA duplex con-
taining a long homologous sequence as the template for strand
exchange and resynthesis, which results in a repair of the DSB
(San Filippo et al., 2008). The HR repair process is error free
and mainly occurs during late S and G2 phases, when sister
chromatids are available as theHR templates. The new synthesis
of long strands during HR requires the incorporation ofmore than
10,000 dNTPs in order to repair a single DSB by strand invasion
(Robert et al., 2011). The RNR-mediated supply of dNTPs is thus
critical to successful HR repair (Burkhalter et al., 2009; Moss
et al., 2010).
Because formation of dTDP specifically requires TMPK func-
tionality, we have hypothesized that blocking TMPK should also
reduce the efficiency of DSB repair and sensitize tumor cells to
genotoxic insults. Using RNA interference, we have previously
shown that TMPK knockdown significantly increases the sensi-
tivity of HCT-116 colon cancer cells to doxorubicin, a topoiso-
merase II inhibitor that induces DSBs in DNA (Hu and Chang,
2008). In comparison, TS knockdown only sensitizes p53-
deficient cells to doxorubicin to a limited extent because of
complementation of TK-mediated dTMP formation. Impor-
tantly, we found that TMPK knockdown does not, on its own,
activate DNA damage responses. It thus functions in a way
that is quite distinct from that of the antimetabolites used in
conventional anticancer therapies, which directly induce geno-
toxicity (Garg et al., 2010). For example, the thymidylate syn-
thase inhibitors 5-FU and 5-FdUrd block the conversion of
dUMP to dTMP, causing dUTP to accumulate and inducing
the formation of 5-FdUTP (Longley et al., 2003). DNA poly-
merases are unable to discriminate between dUTP and dTTP
(Bessman et al., 1958), and, therefore, excessive amounts of
dUTP and 5-FdUTP are misincorporated into DNA, which trig-
gers DNA damage-induced cell death (Ahmad et al., 1998).
Consequently, such antimetabolites are highly toxic to normal
cycling cells and potentially may induce the development of
secondary tumors.
TMPK-knockdown cells are viable and capable of prolifer-
ating (Hu and Chang, 2008). Given the essential function of
TMPK during dTDP formation, this suggests that human tumor
cells have a TMPK isoform. However, it is hard to understand
why TMPK knockdown profoundly affects DNA repair in tumor
cells. Unlike TMPK knockdown, blocking RNR by itself induces
a DNA damage response and blocks DNA repair (Shao et al.,
2006). A recent report has demonstrated that RNR is recruited
to sites of DNA damage as a result of an interaction with
Tip60 via the C-terminal region of the R1 subunit (Niida et al.,
2010a). Disruption of RNR recruitment to sites of DNA damage
affects DSB repair in G1-phase cells but not in S-phase cells.
The explanation for this is that the low levels of dNTPs in
G0/G1-phase cells make the site-specific production of dNTPs
by RNR critical to DNA repair (Ha˚kansson et al., 2006). In this
study, we have provided evidence linking the involvement of
RNR at DNA damage sites to the functional requirement of
TMPK for DNA repair in tumor cells. Additionally, we identified
a cell-permeable inhibitor of hTMPK. Our results further demon-
strate the potential of TMPK inhibitors to be part of mild anti-
cancer therapies.RESULTS
TMPK Contributes to the Repair of DSBs by Preventing
dUTP Incorporation
To assess the role of TMPK in DSB repair, we silenced TMPK
expression in U2OS cells harboring a DR-GFP reporter using
siRNA and performed HR analysis (Pierce et al., 1999). In the
presence of I-SceI endonuclease, which induces DSBs, HR
repair generates intact GFP, which gives a fluorescent readout.
Using flow cytometry analysis, it was found that TMPK knock-
down significantly reduced the efficiency of HR repair, as
determined by measuring the GFP-positive fraction (Figure 1A).
Cell-cycle analysis showed that TMPK knockdown did not
reduce the numbers of U2OS cells in the S and G2/M phases
(Figure 1A and Figure S1A, which is available online), which
excludes the possibility that TMPK knockdown reduces the
number of HR-permissive cells. We also tested the effect of
TMPK knockdown on the repair of doxorubicin-induced DNA
lesions in MDA-MB231 breast cancer cells. Control and
TMPK-knockdown cells were treated with a low dose of doxoru-
bicin (0.1 mM) for 4 hr and then were washed thoroughly with
growth medium. Initially, the number of DNA lesions, as indi-
cated by gH2AX focus staining (Mah et al., 2010), was similar
in these cells to the control (Figure 1B). After recovery for
24 hr, the number of doxorubicin-induced DNA lesions was
reduced in the control cells, indicating that these cells were
capable of repairing the DNA damage induced by exposure to
low-dose doxorubicin. In contrast, the number of gH2AX foci in
the TMPK-knockdown cells was relatively constant and signifi-
cantly higher than in the control. Moreover, TMPK knockdown
on its own had only a slight effect on the growth of MDA-
MB231 cells, which contrastedwith themarked reduction in cells
growth found when cells were exposed to doxorubicin (Figures
S1B and S1C). Thus, TMPK would seem to be essential for
DNA repair in MDA-MB231 cells when they are exposed to
low-dose doxorubicin.
Doxorubicin exposure-induced DSBs are repaired by HR. It is
known that HR involves Rad 51 foci, which is where strand inva-
sion takes place during repair (Holthausen et al., 2010). We
tested the effect of TMPK knockdown on the formation and reso-
lution of Rad 51 foci following exposure to doxorubicin. The
results show that TMPK knockdown did not initially affect
Rad51 focus formation. However, after 24 hr, the number of
Rad 51 foci was significantly reduced in the control cells but
not in TMPK-knockdown cells (Figure 1C). This indicates that
TMPK knockdown prevents the repair of recombinogenic
lesions. We also examined XRCC1 foci, which are known to be
single-strand break-repair (SSBR) markers (Caldecott, 2008).
As expected, very few XRCC1 foci were detected in control
and TMPK knockdown cells immediately after exposure. At
24 hr after recovery, TMPK knockdown cells showed a marked
increase in the number of XRCC1 foci (Figure 1D), which implies
that blocking TMPK promotes the presence of DNA single-
strand breaks (SSBs) formation during HR.
It is well established that SSBs are generated via the removal
of erroneous bases by DNA glycosylases and via apurinic/
apyrimidinic endonuclease (APE)-mediated cleavage at the
abasic sites (Caldecott, 2008). Uracil DNA glycosylases, such
as uracil N-glycosylase (UNG), remove uracil from DNA (KrokanCancer Cell 22, 36–50, July 10, 2012 ª2012 Elsevier Inc. 37
Figure 1. TMPK Knockdown Causes DSB Repair with dUTP Incorporation
(A) Following transfection with TMPK siRNA for 24 hr, U2OS-DR-GFP cells were transfected with pCBA-I-SceI plasmid for 48 hr. The frequency of GFP-positive
cells was measured by FACS analysis. In parallel, cells were fixed with PI staining for FACS analysis and harvested for Western blot analysis.
(B–D) MDA-MB231 cells without and with TMPK shRNA stable expression were exposed to doxorubicin (0.1 mM) for 4 hr and then underwent recovery in
refreshing medium to give gH2AX foci staining (B) (scale bar, 20 mm), Rad51 foci staining (C) (scale bar, 5 mm), and XRCC1 foci staining (D) (scale bar, 5 mm). Each
cell containing gH2AX foci > 10, Rad51 foci > 20, and XRCC1 foci > 5 were counted and expressed as a percentage.
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resulted from the misincorporation of uracil, TMPK-knockdown
cells were infected with lentiviral shRNA for UNG. After recovery
from doxorubicin exposure, it was found that the number of
XRCC1 foci was markedly reduced by UNG knockdown (Fig-
ure 1E and Figure S1D). To verify the presence of uracil in the
genome of the cells after recovery from doxorubicin exposure,
we isolated genomic DNA by in vitro UNG incubation and
analyzed small molecules released from genomic DNA by
mass spectrometric analysis. The mass spectrum showed the
presence of uracil signal in the sample from TMPK knockdown
but not control cells (Figure S1E). Thus, blocking TMPK pro-
motes SSBs as a result of the presence of uracil in the genome
during the repair of doxorubicin-induced DSBs.
We next tested whether the increase in uracil in the genome
was a result of dUTP incorporation. Cellular levels of dUTP
are primarily controlled by dUTPase, an enzyme responsible
for hydrolyzing dUTP to dUMP and pyrophosphate (McIntosh
et al., 1992). Wild-type GFP-dUTPase and a catalytically dead
mutant form of GFP-dUTPase (Figure S1F) were expressed in
TMPK-depleted MDA-MB231 cells. After recovery from doxoru-
bicin exposure, expression of wild-type dUTPase was found
to significantly reduce the number of XRCC1 foci in TMPK-
knockdown cells compared to cells expressing the catalytically
dead dUTPase, which retained a high level of XRCC1 foci (Fig-
ure 1F and Figure S1G). Consistently, gH2AX foci were abolished
by overexpression of wild-type, but not catalytically dead,
dUTPase (Figure S1H). In conclusion, our results show that
TMPK is essential for preventing dUTP incorporation during
the repair of DSBs.
Repair at Sites of DNA Damage Requires Coordination
between RNR and TMPK
It has been estimated that the dUTP/dTTP ratio in cells is
normally within the range 0.3% to 3% (Traut, 1994). TMPK-
knockdown cells retain more than 60% of the dTTP pool
and are able to proliferate albeit a slower rate (Figures S2A
and S2B). Presumably, the cellular level of dTTP is still much
higher in these cells than the level of dUTP. This prompted us
to question why knockdown of TMPK should cause the incorpo-
ration of dUTP during DNA repair. To assess the functional
requirements for this TMPK during DNA repair, MDA-MB231
breast cancer cells were transfected with pEGFP-TMPK(WT) or
pEGFP-TMPK(D15R), a catalytically dead mutant (Figure S2C).
Overexpression of TMPK(WT) resulted in an increased rate of
disappearance of gH2AX foci after recovery from doxorubicin
exposure. In contrast, overexpression of TMPK(D15R) resulted
in the persistence of the gH2AX foci (Figure 2A). It should be
mentioned that, when we overexpressed TMPK(D15R) in
HeLa cells with high transfection efficiency, it was found that
the steady-state level of dTTP was unaffected (Figures S2D(E) Cells were infectedwith lentivirus of LacZ or UNG shRNA for 8 hr. After another
in freshmedium for 24 hr before fixation and XRCC1 foci staining (scale bar, 5 mm).
experiment in (B–E), 100 cells were counted.
(F) Cells were transfected with wild-type and catalytic-dead dUTPase expression
and recovered for XRCC1 staining as described in (E). The numbers of GFP-posi
experiment, 100 GFP-positive cells were counted. All error bars represent SD (n
See also Figure S1.and S2E). Given that functionality of endogenous TMPK does
not seem to be significantly affected by the expression of
TMPK(D15R), the inhibitory effect of TMPK(D15R) on DNA repair
is thus unlikely to be related to the size of the dTTP pool.
The RNR-mediated reaction yields dUDP, which is converted
to dUTP by NDP kinase (Mathews, 2006). TMPK knockdown
results in the incorporation of dUTP during DNA repair, and,
therefore, we examined the effect on repair of blocking the
recruitment of RNR to sites of DNA damage in TMPK-knock-
down MDA-MB231 cells. To this end, we overexpressed YFP
fused to a 90-amino-acid C-terminal fragment of the R1 subunit
(R1C–NLS–YFP), which interferes with the interaction between
endogenous RNR and Tip60 that is required for recruitment to
sites of damage (Niida et al., 2010a). Remarkably, overexpres-
sion of this R1C–NLS–YFP fusion protein abolished the effect
of TMPK knockdown on the number of gH2AX foci during
recovery from doxorubicin exposure (Figure 2B). The effect of
TMPK(D15R) overexpression was also reversed by expression
of R1C–NLS–YFP (Figure 2C). Thus, RNR functionality at sites
of DNA damage requires functional coordination with TMPK in
order to prevent dUTP-mediated lesions from persisting.
In order to determine whether TMPK and RNR are recruited to
sites of DNA damage, we used laser microirradiation to damage
DNA, and it was found that gH2AX and endogenous TMPK and
R2 colocalized along themicroirradiated line (Figure 2D). Consis-
tently, R1was also found colocalized with gH2AX (Figure S2F). In
addition, we transfected cells with an expression vector encod-
ing I-PpoI, which introduces specific DSB in chromosome 1 and
ribosomal DNA (Flick et al., 1998). This system allows analysis of
the recruitment of the repair proteins to specific DSB sites
(Berkovich et al., 2007). We cotransfected cells with pFlag-
TMPK to allow chromatin immunoprecipitation (ChIP). Quantita-
tive ChIP analysis showed the presence of Flag-TMPK at the
I-PpoI cleavage site in chromosome 1 but not at the c-fos
promoter region. gH2AX and the R2 subunit of RNR were also
present at the I-PpoI cleavage site, but histone 3 (H3) occupancy
was not affected by I-PpoI cleavage (Figure 2E). Similar results
were observed for ribosomal DNA compared to the control
gene GAPDH using ChIP analysis, which additionally showed
that the association of UBF, a specific rDNA-binding protein,
was not affected by I-PpoI cleavage (Figure S2G). These results
suggest that TMPK and RNR bind to sites of DNA damage
where they coordinate the site-specific production of balanced
amounts of the four dNTPs needed for repair.
High Levels of R2 Expression after DNA Damage Are
a Determinant of Tumor Cells that Require TMPK for
Repair
We further tested the requirement of TMPK for DNA repair in
another breast cancer cell line, MCF-7, as well as in nontumori-
genic cycling mammary H184B5F5/M10 and MCF10A cells. In36 hr, cells were exposed to doxorubicin (0.1 mM) for 4 hr and allowed to recover
The inset indicates theWestern blot data of UNG, TMPK, andGAPDH. For each
plasmids. After overnight incubation, the cells were treated with doxorubicin
tive cells with > 5 XRCC1 foci per cells are shown in the upper panel. For each
= 3).
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Figure 2. Coordination of TMPK with RNR at Sites of DNA Damage during Repair
(A) MDA-MB231 cells were transfected with pEGFP-TMPK (WT or D15R) followed by doxorubicin exposure and recovered as described in the legend to Fig-
ure 1B. Cells were fixed for gH2AX staining (scale bar, 20 mm). For each experiment, 100 GFP-positive cells were counted.
(B) Cells without and with stable TMPK shRNA expression were transfected with pCMV2-YFP-Nuc (vector) or pCMV2-YFP-Nuc-R1C (R1C) plasmid (scale bar,
5 mm).
(C) Cells were transfected with pEGFP-TMPK (D15R) in combination with pCMV2-YFP-Nuc-R1C (R1C) plasmid as indicated. Following doxorubicin exposure
and recovery for 24 hr, these cells were analyzed by gH2AX foci staining (scale bar, 10 mm). For each experiment, 100 YFP- or GFP-positive cells were counted. All
error bars represent SD (n = 3).
(D) HeLa cells were plated on glasses-like dishes for laser-micro-irradiation. After recovery for 5 min, cells were fixed for gH2AX, TMPK, and R2 immunofluo-
rescence staining (scale bar, 10 mm).
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TMPK and dUTP in DNA Repaira similar manner to that which occurred with MDA-MB231 cells,
TMPK knockdown caused doxorubicin-induced gH2AX foci to
persist in MCF-7 cells. In contrast, DNA repair was unaffected
by TMPK knockdown in H184B5F5/M10 and MCF10A cells
(Figure 3A). We compared expression levels of R2, p53R2,
TMPK, and dUTPase during recovery from DNA damage in
MDA-MB231, MCF-7, H184B5F5/M10, and MCF10A cells (Fig-
ure 3B). Expression of the R2 subunit of RNR and dUTPase was
much higher in MCF-7 cells than in H184B5F5/M10 and
MCF10A cells. In MDA-MB231 cells, the levels of R2 and
dUTPase increased concomitantly between 12 and 48 hr after
doxorubicin exposure, which contrasted with their continuous
decline in H184B5F5/M10 and MCF10A cells. Expression of
p53R2 was very low in MDA-MB231 cells because of the p53
functional deficiency. In MCF-7, H184B5F5/M10, and MCF10A
cells, the expression of p53R2 increased during recovery from
doxorubicin exposure (between 24 and 48 hr). Flow cytometry
analysis demonstrated that the G0/G1-phase cell populations
in H184B5F5/M10 and MCF10A cells were 2–3-fold higher
than those in MDA-MB231 and MCF-7 cells during recovery
from DNA damage (Figure 3C). The larger S and G2/M cell pop-
ulations in MDA-MB231 and MCF-7 cells during recovery indi-
cate a lower stringency of checkpoint control in response to
genome insults in these cells. It has been shown that G2/M
synchronization by nocodazole treatment promotes HR (Katada
et al., 2012). We further treated H184B5F5/M10 cells with noco-
dazole overnight to block mitotic progression, which increased
the G2/M cell population as confirmed by flow cytometry (Fig-
ure 3D and Figure S3A). It was noted that the level of R2 was
decreased in nocodazole-treated cells (Figure 3D) probably
because of mitotic degradation (Chabes et al., 2003). After
washing out nocodazole, the released cells at 24 hr had less
than 20% of G2/M population (Figure S3). Very differently, the
nocodazole released cells after doxorubicin exposure, and
recovery at 24 hr still contained more than 50% G2/M popula-
tion. Under this situation, these H184B5F5/M10 cells with
increased G2/M cell numbers were still insensitive to TMPK
knockdown during DNA repair (Figure 3E). Therefore, the lack
of TMPK sensitivity in DNA repair in H184B5F5/M10 cells is
unlikely due to less HR-permissive cells after doxorubicin expo-
sure. We also compared the cell growth rates of these four cell
lines. Under our experimental conditions, H184B5F5/M10 and
MCF10A cells proliferated more rapidly than did MDA-MB231
and MCF-7 cells (Figure S3B). These results indicate that the
differences in sensitivity to TMPK knockdown in the context
of DNA repair efficiency are not correlated with the proliferation
rate of the cell lines nor are they determined by the cell cycle
distribution.
Given that RNR at sites of DNA damage contributes to the
incorporation of dUTP in TMPK-knockdown MDA-MB231 cells,
we tested whether elevation of R2 levels in tumor cells is a major
factor determining the requirement for TMPK during DNA repair.
MCF-7 cells express high levels of R2 and contain p53R2 at(E) HEK293T cells were transfected with HA-ER-I-PpoI or empty vector together w
with the indicated antibody using a primer pair adjacent to the I-PpoI cleavage site
a genomic DNA control because it has no I-PpoI site. Datawere normalized by IgG
experiments.
See also Figure S2.a level similar to that found in H184B5F5/M10 andMCF10A cells.
In this context, we reduced the R2 level in MCF-7 cells to a level
that was similar to that found in H184B5F5/M10 cells by trans-
fection with siRNA and then exposed the cells to doxorubicin
(Figure 4A). Flow cytometric analysis showed that a reduction
in R2 levels by siRNA transfection alone or in combination with
TMPK knockdown did not decrease the S/G2 cell population
significantly (Figure 4B and Figure S4A). At 24 hr after recovery,
gH2AX foci were still present in cells transfected with either R2
siRNA alone or R2 and TMPK siRNAs (data not shown). How-
ever, at 36 hr after recovery, it was found that a reduction
in R2 expression rescued DNA repair in TMPK-knockdown
MCF-7 cells (Figures 4C and 4D). Therefore, it would seem that
the level of R2 is able to determine whether TMPK knockdown
affects DNA repair.
We next selected a MCF10A cell clone with constitutive eleva-
tion of R2 expression using a lentiviral vector of mCherry-R2.
This cell line was then subjected to TMPK knockdown and
DNA repair analysis (Figure 4E). The results showed that overex-
pression of R2 in combination with TMPK-knockdown caused
Rad 51 foci to persist at 24 hr after recovery inMCF10A cells (Fig-
ure 4F and Figure S4B) and also promoted XRCC1 foci formation
(Figure S4C). As a consequence of these changes, such cells re-
mained gH2AX positive (Figure 4G). The cell-cycle analysis of
these cells showed that constitutive elevation of R2 expression
did not increase S/G2 cell population (Figure S4D). Thus, eleva-
tion of R2 expression renders DNA repair in MCF10A cells sensi-
tive to TMPK knockdown without altering cell-cycle distribution.
Taken together, the above results demonstrate that an increase
in the level of R2 and the recruitment of RNR to sites of DNA
damage are the key factors that make TMPK a critical factor
for DNA repair in tumor cells. In other words, increased RNR
activity at sites of DNA damage in tumor cells needs to be func-
tionally coordinated with the presence of TMPK to prevent dUTP
incorporation.
Screening and Characterization of YMU1 as an hTMPK
Inhibitor
On the basis of the fact that there is a specific functional require-
ment for TMPK during DNA repair in tumor cells that have
elevated levels of R2 expression, we next searched for inhibitors
of hTMPK that might be useful as an approach to selectively
sensitizing tumor cells to doxorubicin. Using a luciferase-
coupled TMPK assay (Hu and Chang, 2010) in which the inhibi-
tion of TMPK leaves more ATP available for the generation of
luminescence by luciferase (Figure 5A), we screened a library
of 21,120 small molecules and identified one highly potent
compound, YMU1, the structure of which is shown in Figure 5B.
An enzymatic assay confirmed that YMU1 is an hTMPK inhibitor
with an IC50 of 0.61 ± 0.02 mM (Figure 5C) and that the compound
has no inhibitory effect on the activity of purified thymidine
kinase 1 (TK1) (Figure 5D). To investigate the structure-activity
relationship, two fragments of YMU1 (D3 and D6), one isomerith pFlag-TMPK. After 18 hr, cells were collected and used for qChIP analysis
(280 bp 50 to the I-PpoI cut site) in chromosome 1. The c-fos promoter serves as
control and calculated relative to total input (percentage) from two independent
Cancer Cell 22, 36–50, July 10, 2012 ª2012 Elsevier Inc. 41
Figure 3. Correlation of the Cellular Level of R2 with the Requirement for TMPK during DNA Repair
(A) MCF-7, H184B5F5/M10, and MCF-10A cells were transfected with TMPK siRNA. These cells were exposed to doxorubicin and recovered for gH2AX foci
staining (scale bar, 20 mm), as described in the legend to Figure 1B. For each experiment, 100 cells were counted.
(B and C) Cells were exposed to doxorubicin and then underwent recovery. Cells were harvested at the indicated time points for Western blot (B) and flow
cytometry (C) analysis.
(D and E) H184B5F5/M10 cells were transfected with TMPK siRNA for 36 hr and then treated with 500 ng/ml of nocodazole overnight. (D) A proportion of cells
were harvested for Western blot and FACS analysis. The rest of cells were exposed to doxorubicin (0.2 mM) for 2 hr and allowed to recover with fresh medium.
(E) At the indicated time of recovery, cells were fixed for gH2AX foci staining and FACS analysis. For each experiment, 200 cells were counted.
See also Figure S3.
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Figure 4. Effect of R2 Expression Level on DNA Repair in Response to TMPK Knockdown
(A and B) MCF-7 cells were transfected with siRNA of TMPK, R2, or TMPK/R2 for 36 hr. A proportion of cells were harvested for Western blot (A) and FACS (B)
analysis. The rest of cells were exposed to doxorubicin (0.1 mM) for 4 hr.
(C and D) Cells at the indicated time points were analyzed by gH2AX foci staining, and 150 cells were counted to indicate the percentage of gH2AX foci-positive
cells, and representative images are shown (D) (scale bar, 20 mm).
(E–G) MCF10A clones stably expressing mCherry or mCherry-R2 were selected and transfected with TMPK siRNA for 36 hr. (E) Western blot analysis of the cells.
(F and G) After exposure to doxorubicin and recovery at indicated time, cells were fixed for Rad 51 (F) and gH2AX foci staining (G) (scale bar, 20 mm). For each
experiment in (F) and (G), more than 150 cells were counted. All error bars represent SD (n = 3).
See also Figure S4.
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TMPK and dUTP in DNA Repairof YMU1 (D7), and a benzeneisothiazolone derivative of YMU1
(D8) were synthesized (Figure 5B). Neither D6 (the piperazine
fragment of YMU1) nor D7 (the O-alkylation isomer of YMU1)
showed any inhibition of hTMPK, whereas D3 (the pyridinoiso-
thiazolone fragment of YMU1) exhibited weak inhibitory activity.
Interestingly and in contrast to the above three compounds, the
benzeneisothiazolone derivative D8 also displayed considerable
inhibitory activity.The mode of inhibition of YMU1 was determined by preincu-
bating different concentrations of YMU1 with purified hTMPK
protein and measuring the initial velocity in a conventional
TMPK assay. The Km and Vmax values were determined by
nonlinear regression analysis and are summarized in Table 1.
Preincubation with YMU1 reduced the Vmax of hTMPK in
a concentration-dependent manner while increasing the Km for
ATPwithout significantly affecting theKm for TMP. The inhibitionCancer Cell 22, 36–50, July 10, 2012 ª2012 Elsevier Inc. 43
Figure 5. Identification of an hTMPK Inhib-
itor
(A) A screen for hTMPK inhibitors by luciferase-
coupled assay.
(B) The chemical structures of YMU1 and related
molecules. The chemical synthesis scheme of
YMU1 and related compounds is presented in
Supplemental Experimental Procedures.
(C) Effect of YMU1 and derivative compounds on
hTMPK inhibition. Activity analysis of purified
hTMPK protein (0.5 mg) after 10 min of prein-
cubation with compounds using luciferase-
coupled TMPK analysis.
(D) Activity of purified TMPK (0.5 mg) and GST-
hTK1 protein (5 mg) that had been preincubated
with YMU1 for 10min prior to the activity assay. All
error bars represent SD (n = 4).
(E) Molecular models of the TMPK-YMU1 com-
plex. Left panel: TMPK/ATP/Mg2+; right panel:
TMPK/YMU1. The TMPK is represented as sur-
face electrostatic potential (upper) and a structural
ribbon (lower). ATP and YMU1 are shown as green
and blue stick models, respectively, with colored
atoms (O, red; S, yellow; P, orange). TMP is shown
as a white backbone and Mg2+ is shown in purple.
The arrow indicates the position of Asp15.
See also Figure S5.
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TMPK and dUTP in DNA Repairconstant (Ki) was determined by kinetic analysis to be 0.22 ±
0.03 mM (Table 1). Molecular docking studies were performed
to analyze the mechanism of inhibition of TMPK by YMU1. The
results of the kinetic studies suggest that YMU1 probably affects
the ATP-binding pocket of TMPK. Using the crystal structure of
TMPK with TMP and Mg+2, it was possible to dock YMU1 into
the ATP pocket. During this docking complex, YMU1 prevents
oneMg+2 ion from interacting with the Asp15 residue in the cata-
lytic domain (Figure 5E). Because a mutation of Asp15 to Arg is
known to abrogate TMPK catalytic function, it is possible that
preincubation of TMPK with YMU1 hinders the functionality of
the Mg+2 ion pointing toward the catalytic Asp15 residue in the
ATP pocket, thereby reducing catalytic efficiency. The docking
of D3, D6, and D7 at these sites was found to not prevent
Asp15 from interacting with Mg+2 and therefore suggests why
these compounds do not inhibit TMPK.
YMU1 reduced cellular dTTP levels by about 30%–40%
(Figure S5). Transfection of cells with siRNA to suppress TMPK
expression reduced the size of the dTTP pool to a similar extent.
YMU1 treatment did not cause any further reduction of the
dTTP pool in TMPK-knockdown cells. The levels of dATP,
dCTP, and dGTP were unaltered in both YMU1-treated and
TMPK-knockdown cells (Figure S5). These results indicate that44 Cancer Cell 22, 36–50, July 10, 2012 ª2012 Elsevier Inc.YMU1 specifically reduces dTTP level
and that the ability of YMU1 to reduce
dTTP level is dependent on the presence
of TMPK in the cells.
YMU1 Is Not Toxic to the Genome
and, Similar to TMPK Silencing,
Impairs DSB Repair
Inhibition of TS by FdUrd causes genome
toxicity (Longley et al., 2003). Given theshared role of TMPK and TS in dTTP synthesis, we next
compared the effects of blocking TMPK and TS on the induction
of DNA damage of either shRNA interference or inhibitor treat-
ment. As indicated by gH2AX staining, TS silencing and FdUrd
treatment induced severe DNA damage, whereas TMPK
silencing and YMU1 treatment did not (Figure 6A). We also
compared the effects of YMU1 and FdUrd on the viability of non-
tumorigenic H184B5F5/M10 and MCF10A mammary cycling
cells and MCF-7 and HCT-116 p53/ tumor cells. A colony
assay indicated that FdUrd, but not YMU1, caused cell death
in all of these cells (Figure 6B). Therefore, unlike blocking TS, tar-
geting TMPK does not, on its own, cause genome toxicity or
cytotoxicity. We also performed MTS assays using human
primary bone marrow mesenchymal stem cells (HBMSC), renal
cortical epithelial cells (HRCE), mammary epithelial cells
(HMEC), and breast tumor MDA-MB231 cells and found that
YMU1 had very little effect on cell growth (Figure S6A).
We next examined the effect of YMU1 on the repair of doxoru-
bicin-induced DNA lesions in MDA-MB231 and H184B5F5/M10
cells after recovery from low-dose doxorubicin treatment.
Notably, in H184B5F5/M10 cells, YMU1 treatment did not affect
the numbers of DNA lesions formed, as determined by gH2AX
focus staining. Similar to TMPK knockdown, pretreatment with
Table 1. Effect of YMU1 on the Kinetic Parameters of Purified
Human Thymidylate Kinase
YMU1
compound (mM)
Km for
TMP (mM)
Vmax
(nmol/min/mg) Ki (mM)
0 28.7 ± 2.4 376.6 ± 14.5 0.22 ± 0.03
0.125 26.5 ± 2.8 258.9 ± 12.4
0.25 27.5 ± 4.0 180.6 ± 11.8
0.5 28.0 ± 4.3 91.8 ± 6.4
YMU1
compound (mM)
Km for
ATP (mM)
Vmax
(nmol/min/mg)
Ki (mM)
0 25.7 ± 2.4 367.2 ± 9.4 0.18 ± 0.06
0.25 29.5 ± 5.6 212.0 ± 10.3
0.5 41.2 ± 7.4 94.8 ± 6.9
1 43.8 ± 3.3 55.7 ± 1.3
For the Ki value determination, YMU1 at the indicated concentration was
preincubated with 0.5 mg of purified hTMPK protein for 10 min, and the
initial velocity of the TMPK reaction wasmeasured at different concentra-
tions of TMP (2–200 mM) in the presence of ATP (1 mM) or at different
concentrations of ATP (5–1000 mM) in the presence of TMP (200 mM)
using a NADH-coupled TMPK assay. Data represent mean ± SD, n = 4.
Data obtained from the nonlinear regression analysis were used to calcu-
late the Km and Vmax. The Ki value of YMU1 for hTMPK was calculated
from the equation of Ki = [I] / (Vmax / Vmax’  1), where [I] and Vmax’ are
the YMU1 compound concentration andmaximal velocity in the presence
of YMU1, respectively. TheKi value represents amean value derived from
three different YMU1 concentrations.
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TMPK and dUTP in DNA RepairYMU1 caused over 70% of the MDA-MB231 cells to remain
gH2AX positive at 48 hr after doxorubicin exposure (Figure 6C)
but did not affect cell-cycle progression during recovery (Fig-
ure S6B). Comet assay analysis further confirmed that YMU1
treatment impaired DNA repair in MDA-MB231 cells exposed
to doxorubicin (Figure S6C). Overexpression of GFP-TMPK
rendered MDA-MB231 cells resistant to the YMU1-mediated
persistence of DNA lesions, supporting the idea that YMU1
exerts its effect by targeting TMPK (Figure 6D). Overexpression
of TMPK(WT) in YMU1-treated HeLa cells with high transfection
efficiency restored the level of dTTP (Figure 6E). Similar to siRNA
knockdown, YMU1 treatment also led to the persistence of Rad
51 foci and an increase in XRCC1 focus formation that was abol-
ished by UNG depletion (Figures 6F–6H). The inhibitory effect of
YMU1 on DNA repair was reversed by overexpression of either
dUTPase or a 90-amino-acid C-terminal fragment of the R1
subunit of RNR (Figures 6I and 6J), which confirms that the effect
of YMU1 on repair toxicity is dependent on the amount of dUTP
present at damage sites and recruitment of RNR to the damage
sites. Furthermore, YMU did not inhibit dUTPase in vitro
(Figure S6D).
YMU1 Sensitizes Malignant Tumor Cells to Doxorubicin
In Vitro and In Vivo
Next, various human cancer cell lines were treated with YMU1,
the D6 compound, or the D7 compound for 72 hr to test the
potential of TMPK inhibition in relation to doxorubicin sensitiza-
tion. After exposure to different concentration of doxorubicin
for 4 hr, cells were subjected to viability analysis, and the IC50
value for doxorubicin for each cell line was determined (Fig-
ure 7A). YMU1 treatment increased doxorubicin sensitivityin HT-29, HCT-116 p53+/+, HCT-116 p53/, H1299, CL1-0,
U2OS, MDA-MB231, MDA-MB468, and SaoS2 cells by
3–35-fold. Two HR defective cell lines, HCC1937 and Capan1
deficient in BRCA1 and 2 (Nagaraju and Scully, 2007; Powell
and Kachnic, 2003), were not responsive to YMU1 treatment.
YMU1 had little effect on the doxorubicin IC50 of mammary
cycling H184B5F5/M10 and MCF10A cells, IMR-90 embryonic
lung fibroblasts, and primary HMEC and HRCE. The inactive
compoundsD6andD7 shown in Figures 5Band5Cdid not cause
doxorubicin sensitization in any of these cell lines. Western blot
analysis indicated that all tumor cells that were sensitized by
YMU1 treatment showed elevated levels of R2 expression after
doxorubicin exposure (Figure 7B). A colony assay further showed
that YMU1 markedly enhanced the lethal effects of doxorubicin
(0.1 mM) in HCT-116 and MCF-7 cells (Figure 7C). TMPK knock-
down was unable to further sensitize YMU-treated MDA-
MB231 cells to doxorubicin (Figure S7A), suggesting that the
specificity of YMU1 in terms of doxorubicin sensitization is re-
lated to the drug targeting TMPK. Overexpression of wild-type
dUTPase prevented YMU1/doxorubicin-induced apoptosis, as
revealed by reduced Annexin V staining (Figure S7B).
We also used an in vivo xenograft model using HCT-116
p53/ cells inoculated into nude mice to examine the effect of
YMU1 as an adjuvant on sensitization to low-dose doxorubicin
treatment. Tumor growth rates in mice treated with either doxo-
rubicin alone or YMU1 alone were similar to those in control
animals. In contrast, the growth of tumors was much slower in
the YMU1/doxorubicin double-treated mice (Figure 7D). Two
weeks after the last injections were administered, mice were
sacrificed, and tumor weights measured. We observed excellent
tumor suppression in the YMU1/doxorubicin double-treated
mice, with an average tumor size that was 25% of the control
mice (Figure 7E). Under these experimental conditions, the
tumor sizes remained similar in mice treated with doxorubicin
alone or YMU1 alone. In agreement with these tumor-growth
data, the tumor proliferation index, determined by measuring
Ki 67 immunostaining, was clearly reduced in the nude mice
treated with both YMU1 and doxorubicin (Figure 7F). We also
treated mice bearing larger tumors of various different sizes
formed by HCT-116 p53+/+ cell implantation. The results consis-
tently showed that the joint therapy of YMU1 with doxorubicin
significantly suppressed tumor growth (Figure S7C). Further-
more, Balb/c mice were treated with YMU1 for 4 weeks, using
a 2-fold higher dose regimen than that used in the tumor xeno-
graft study. YMU1 treatment did not alter mouse body weight
over the course of 4 weeks. Additionally, the weights of various
organs (heart, liver, spleen, lungs, and kidneys) and the results
of hematological analyses of the YMU1-treated mice were
similar to those of the control mice (Table S1). Taken together,
these results indicate that, on its own, YMU1 seems to produce
no obvious toxic effects in normal mice and that, in conjunction
with low-dose doxorubicin, YMU1 suppresses tumor growth in
mice.
DISCUSSION
In this study, we provide insights into the functional requirement
of TMPK for DNA repair in tumor cells. Our results suggest that
RNR at the sites of DNA damage may be responsible for theCancer Cell 22, 36–50, July 10, 2012 ª2012 Elsevier Inc. 45
Figure 6. Effect of YMU1 on Genomic Toxicity and DNA Repair
(A) HCT-116 p53/ cells were infectedwith lentivirus of TMPK or TS shRNA. In parallel, cells were treatedwith YMU1 (2 mM) for 2 days, or 5-fluoro-20deoxyuridine
(FdUrd, 2 mM) for 1 day. These cells were fixed for gH2AX foci staining (scale bar, 20 mm) and Western blot analysis.
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TMPK and dUTP in DNA Repairsite-specific production of dUTP. Theoretically, the formation of
dUMP by dUTPase and the TS-mediated reaction that converts
dUMP to dTMP should limit the amount of cellular dUTP.
However, blocking TMPK function causes the incorporation of
dUTP during DNA repair in tumor cells, a response that is depen-
dent on the recruitment of RNR to the sites of damage; these
findings reveal the physiological complexity of the site-specific
production of dUTP by the RNR. We propose that blocking
TMPK reduces the rate of dTTP formation at sites of damage,
whereas increased RNR function is able to increase site-specific
dUTP production. Because HR requires the incorporation of
more than 10,000 dNTPs to repair each DSB, the probability of
dUTP incorporation is increased, which leads to persistent
lesions. Given that RNR activity is elevated in tumor cells after
DNA damage, blocking TMPK function sensitizes tumor cells
to doxorubicin (Figure 7G). In agreement with our hypothesis,
we found that HR-defective tumor cells were not responsive to
the blocking of TMPK during the repair of doxorubicin-induced
lesions.
Expression of the R2 subunit of RNR and dUTPase is cell-
cycle regulated, peaking during the S and G2/M phases (Ladner
and Caradonna, 1997; Nordlund and Reichard, 2006). Malignant
tumor cells have cell-cycle checkpoint defects (Kastan and
Bartek, 2004). Therefore, tumor cells recovering from low
dosage of DNA damage have greater S-phase and G2/M-phase
populations, during which HR-mediated DNA repair can take
place with an increase of R2 expression, and this has a require-
ment for TMPK functionality. In contrast, the S-phase population
is reduced in nontumorigenic cycling cells during recovery from
DNA damage because of the presence of an intact checkpoint
control. As a result, these cycling cells express even lower
amounts of R2, which may further limit dUDP formation.
Because nontumorigenic cycling cells after DNA damage have
fewer S/G2 cells, the question is whether the R2 level or cell-
cycle phase permissive for HR determines the requirement for
TMPK during DNA repair. In this study, we provide evidence
that the manipulation of increasing the G2/M-phase cell does
not make nontumorigenic cycling cells sensitive to TMPK knock-
down during DNA repair, whereas enforced expression of R2
does. Because MCF10A and H184B5F5/M10 nontumorigenic
cells do not grow any slower than MDA-MB231 and MCF7 cells,
these results led us to conclude that the elevation of R2 after(B) H184B5F5/M10 cells were seeded at 5,000 cells/100 mm-dish. MCF10A, MCF
600 cells/well. Following an overnight incubation, the cells were treated with YMU
were fixed and stained by crystal violet.
(C) Cells were pretreated with vehicle or YMU1 (2 mM) for 72 hr and then exposed t
fixed for gH2AX foci staining at the indicated time.
(D) MDA-MB231 cells after vehicle or YMU1 (2 mM) treatment for 48 hr were transf
cells were exposed to doxorubicin and recovered as described above. At 24 hr,
(E) HeLa cells were treated with vehicle or YMU1 (10 mM) for 24 hr and transfected
and dTTP level analysis.
(F and G) MDA-MB231 cells pretreated with vehicle or YMU1 (2 mM) for 72 hr, the
foci (F) and XRCC1 foci (G) staining.
(H) Cells were infected with lentivirus carrying LacZ or UNG shRNA for 8 hr. After
foci staining. Inset indicates the levels of UNG protein by Western blotting analy
(I and J) MDA-MB231 cells pretreated with YMU1 (2 mM) for 48 hr were transfect
exposed to doxorubicin and then underwent recovery as described above. After 2
GFP-positive or YFP-positive cells were counted. Error bars represent SD (n = 3
See also Figure S6.DNA damage is a key factor affecting the requirement for
TMPK in the repair of doxorubicin-induced DNA lesions. In
view of the elevation of R2 expression in tumor cells being asso-
ciated with their continued S/G2 progression after low dosage of
DNA damage, checkpoint defects in tumor cells would seem to
be closely related to the requirement for TMPK during DNA
repair. If so, it is possible that patients with tumor containing
a high R2/TMPK ratio should be more responsive to doxorubicin
therapy. Because expression levels of R2 and TMPK are con-
trolled by transcription and proteolysis, it is necessary to
generate new TMPK antibody applicable for immunohistochem-
ical analysis. In addition, such an analysis in tumor samples from
patients before chemotherapy may not be informative for pre-
dicting response, because some tumors do not express high
levels of R2 until with genotoxic treatment.
Notably, normal cycling cells contain appreciable levels of the
p53R2 subunit, which is capable of forming functional RNR
at sites of DNA damage. This opens up the question as to
why DNA repair in normal cycling cells is not affected by
TMPK knockdown. One plausible explanation is that R2 has
a 4.7-fold higher binding affinity for R1 than does p53R2 (Shao
et al., 2004). It is possible that the low affinity of p53R2 for the
R1 subunit reduces the efficiency of the RNR and minimizes
the site-specific production of dUTP in normal cycling cells.
This would thereby abolish the functional requirement for
TMPK at sites of DNA damage repair. Indeed, enforced expres-
sion of R2 in normal cycling cells causes an impairment of DNA
repair in TMPK knockdown cells, which supports our conclusion
that DNA repair toxicity induced by TMPK knockdown is linked
to an increase in RNR functionality. Expression of R2 and
p53R2 has been found to be upregulated in many types of
cancer cells in patients (Yanamoto et al., 2003; Zhang et al.,
2009). Tumors form in transgenic mice overexpressing R2 or
p53R2 in the lungs (Xu et al., 2008). Whether the side effects of
dUTP formation by RNR at sites of DNA damage are related to
their oncogenic potential remains to be investigated. Neverthe-
less, it is noteworthy that p53R2 predicts better survival in
patients with colorectal cancer, whereas R2 level is correlated
with increased aggressiveness of tumors (Liu et al., 2011).
Expression of an RNRmutant defective in dATP feedback inhibi-
tion in yeast causes elevation of dNTP, which is accompanied by
an inhibition of cell-cycle progression and the DNA damage-7, and HCT-116 p53/ cells were seeded onto 6-well plates at the density of
1 or FdUrd at the indicated concentration twice a week. After 14 days, colonies
o doxorubicin (0.1 mM) for 4 hr. After replacing with freshmedium, the cells were
ected with pEGFP-N1or pEGFP-TMPK plasmid. After incubation overnight, the
the cells were analyzed by gH2AX foci staining.
with GFP or GFP-TMPK (WT). After 48 hr, cells were harvested for Western blot
n exposed to doxorubicin, followed by recovery as described above for Rad51
exposure to doxorubicin and recovery for 24 hr, the cells were fixed for XRCC1
sis. For each experiment in (C–G), more than 100 of the cells were counted.
ed with indicated plasmid or shRNA. After overnight incubation, the cells were
4 hr, the cells were analyzed by gH2AX foci staining. For each experiment, 100
).
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Figure 7. In Vitro and In Vivo Effect of YMU1 on Doxorubicin Sensitization
(A) Various cell lines were pretreated with vehicle, YMU1, D6, or D7 for 3 days. D6 and D7 are inactive molecules shown in Figure 5B. The cells were exposed to
different concentration of doxorubicin for 4 hr. After 48 hr of recovery from doxorubicin exposure, the cells were subjected toMTS assay in quadruplicate, and the
IC50 for doxorubicin was determined. The enhancement (fold) of doxorubicin sensitivity for each cell line was calculated. Error bars represent SD (n = 3). The inset
indicates the IC50 value of doxorubicin for each cell line.
(B) Cells (13 106) were plated in a 60 mm dish. After an overnight incubation, cells were exposed to without or with doxorubicin (0.5 mM) for 4 hr and allowed to
recover in fresh medium for 16 hr. The cells were then harvested for western blot analysis.
(C) After treatment with vehicle or YMU1 for 72 hr, the cells were exposed to 0.1 mMdoxorubicin for 4 hr and then seeded onto a 100 mm-dish at 5,000 cells/dish.
Following an overnight incubation, the cells were refreshed with growth medium for 14 days of incubation for colony formation.
(D) HCT-116 p53/ cells were subcutaneously implanted in the right flank of Balb/c nude mice. The arrow indicated the time when drug treatment was stopped.
The tumor volume was determined.
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TMPK and dUTP in DNA Repaircheckpoint (Chabes and Stillman, 2007). Whether this phenom-
enon involves dUTP formation is also worthy of investigation.
Our findings suggest that a tumor context with checkpoint
defect to allow an R2 elevation after DNA damage makes
TMPK an Achilles heel for doxorubicin sensitization. To substan-
tiate this idea, we identified a TMPK inhibitor, YMU1. We found
that YMU1 increases doxorubicin sensitivity in a variety of tumor
cells. The mice therapy experiments also prove that YMU1
in conjunction with sublethal dose of doxorubicin greatly
suppresses tumor growth. Most importantly, YMU1 on its own
did not produce genotoxic effects in cells or mice. Although TS
inhibitors and other nucleotide metabolite blockers have also
been used as chemosensitizers (Garg et al., 2010), it should be
emphasized that these anticancer agents are toxic to the
genomic DNA in normal cycling cells as well. Their therapeutic
effect stems solely from their ability to cause extensive DNA
damage by which they produce nonspecific toxicity. We pro-
pose that the therapeutic advantage of a TMPK inhibitor over
these conventional compounds is the fact that it shows a specific
toxicity toward malignant cells that contain DNA lesions with
increased levels of R2 expression. Here, we proposed that
YMU1 is a promising lead compound for the development of
a very mild chemosensitization regimen that primes tumor cells
and makes them sensitive to sublethal doses of doxorubicin;
the result should involve lethality that targets these tumor cells
while causing minimal side effects with respect to normal cycling
cells.
EXPERIMENTAL PROCEDURES
Chemistry
Compound YMU1, ethyl 4-(2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-
2(3H)-yl)acetyl)piperazine-1-carboxylate, was synthesized using 2-chloro-4,6-
dimethylnicotinonitrile as a starting material. See Supplemental Experimental
Procedures for synthetic schemes and procedures; additional characterization
data are available upon request.
Homologous Recombination Assay
U2OS DR-GFP cells with the integrated homologous recombination reporter
DR-GFP (Pierce et al., 1999) were transfected with TMPK siRNA, which was
followed by transfection with the I-SceI expression vector (pCBA-I-SceI) for
48 hr. The recombination efficiency was examined by flow cytometric analysis
of the frequency of GFP+ cells.
In Vivo Chemotherapy
All mice experiments were approved by the biosafety committee of National
Yang-Ming University and conformed to the national guidelines and regula-
tions. Female BALB/c AnN.Cg-Foxnlnu/Crl Nurl mice 6–8 weeks of age
(National Laboratory Animal Center, Taiwan) were used for the tumor xenograft
model. HCT-116 p53/ cells (1 3 106) were subcutaneously implanted in the
right flank of each mouse. Treatment began when the tumor size was about
1 mm3. Mice (n = 32) were randomly allocated to four groups, namely vehicle
(15% TEG), doxorubicin (1.25 mg/kg twice a week), YMU1 (5 mg/kg thrice
a week), and YMU (5 mg/kg thrice a week) combined with doxorubicin
(1.25 mg/kg twice a week). Mice were administered with the indicated treat-(E) After 2 weeks recovered from treatment, the mice were sacrificed to allow tu
(F) Ki 67 proliferation marker staining of a tumor is shown in the lower panel (sca
(G) Model of doxorubicin sensitization by YMU1 in malignant cancer cells. Both R
breaks, where dATP, dGTP, dCTP, dTTP, and dUTP are synthesized in a site-spec
sites, which causes futile DNA repair due to dUTP incorporation.
See also Figure S7 and Table S1.ment by intraperitoneal injection for four weeks, after which the mice were
kept in a drug-free condition for additional two weeks. The tumor size was
measured every day after the initiation of drug treatment by electronic caliper.
Tumor volume = length (mm) 3 width2 (mm2) / 2.
Statistical Analyses
A two-tailed Student’s t test was used to assess DNA lesions, tumor size, and
tumor weight (*p < 0.05, **p < 0.01). Data are presented asmean ± SD. All other
experimental procedures are described in the Supplemental Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.ccr.2012.04.038.
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